

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

ARGENTUM PHARMACEUTICALS LLC

Petitioner

v.

CIPLA LIMITED

Patent Owner

---

Case No. IPR2017-00807

U.S. Patent No. 8,168,620

---

**CIPLA LTD.'S UPDATED EXHIBIT LIST**

***Mail Stop "PATENT BOARD"***  
Patent Trial and Appeal Board  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

| <b><i>Cipla's Exhibit #</i></b> | <b><i>Description</i></b>  |
|---------------------------------|--|
| 2001                            | Warner Carr, M.D. Declaration  |
| 2002                            | Warner Carr, M.D. <i>Curriculum Vitae</i>  |
| 2003                            | Alexander Dominic D'Addio, Ph.D. Declaration   |
| 2004                            | Alexander Dominic D'Addio, Ph.D. <i>Curriculum Vitae</i>   |
| 2005                            | John C. Jarosz Declaration   |
| 2006                            | John C. Jarosz <i>Curriculum Vitae</i>   |
| 2007                            | Hugh David Charles Smyth, Ph.D. Declaration  |
| 2008                            | Hugh David Charles Smyth, Ph.D. <i>Curriculum Vitae</i>  |
| 2009                            | Complaint for Patent Infringement, December 2, 2014, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-UNA (D. Del.)   |
| 2010                            | Complaint for Patent Infringement, September 9, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Perrigo UK Finko Limited Partnership, Perrigo Company and Perrigo Pharmaceuticals Co.</i> , Case No. 1:16-cv-00794-LPS (D. Del.) |
| 2011                            | Expert Report of Robert P. Schleimer, Ph.D., August 19, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)  |
| 2012                            | Expert Rebuttal Report of Robert P. Schleimer, Ph.D., July 29, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)   |
| 2013                            | Expert Reply Report of Robert P. Schleimer, Ph.D., August 19, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)  |
| 2014                            | Dr. Maureen Donovan Deposition transcript, October 7, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)  |
| 2015                            | Expert Report of Maureen D. Donovan, Ph.D., June 30, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)   |

| <b><i>Cipla's Exhibit #</i></b> | <b><i>Description</i></b>   |
|---------------------------------|---|
| 2016                            | Expert Reply Report of Maureen D. Donovan, Ph.D., August 19, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)                        |
| 2017                            | Publicly Filed Proposed Joint Pretrial Order, November 10, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D.I.137) (Redactions in Original) |
| 2018                            | Bench Trial Transcript, Volume A, December 13, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)                                      |
| 2019                            | Bench Trial Transcript, Volume B, December 14, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)                                      |
| 2020                            | Bench Trial Transcript, Volume C, December 15, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)                                      |
| 2021                            | Bench Trial Transcript, Volume D, December 16, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)                                      |
| 2022                            | Plaintiffs' Proposed Findings of Fact, January 10, 2017, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 155)                       |
| 2023                            | Defendants' Proposed Finding of Facts, January 10, 2017, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 156)                       |
| 2024                            | Defendants' Opening Post-Trial Brief, January 24, 2017, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.) (D.I. 158)                        |
| 2025                            | Dr. Robert Schleimer Deposition transcript, September 29, 2016, <i>Meda Pharmaceuticals Inc. and Cipla Ltd., v. Apotex Inc. and Apotex Corp.</i> , Case No. 1:14-cv-01453-LPS (D. Del.)                           |
| 2026                            | Gennaro, A. R. <i>Remington's Pharmaceutical Sciences</i> (17 <sup>th</sup> ed., 1985), Ch. 80: 1455-1477; Ch. 82: 1478-1491; Ch. 84:1492-1517  |

| <i>Cipla's Exhibit #</i> | <i>Description</i>   |
|--------------------------|--|
| 2027                     | Accolate Approval Letter and Label, Application Number 20-547/S011, Zeneca Pharmaceuticals   |
| 2028                     | Avomeen Analytical Services Report, June 30, 2016 (PTX0129)  |
| 2029                     | Expert Report of Dr. Matthew J. Herpin and Corresponding Documents (PTX1663)   |
| 2030                     | Expert Report of Dr. Ramprakash Govindarajan and Corresponding Documents (PTX1664)   |
| 2031                     | Duonase Imitator Product Labels (PTX0026)  |
| 2032                     | Allegra-D Approval Letter, Application Number 20786, Approved December 24, 1997, (PTX0126)   |
| 2033                     | Intentionally Left Blank   |
| 2034                     | <i>Physicians' Desk Reference</i> , 54 <sup>th</sup> ed., pp. 1343-1344, 2404-2406, 2781-2783 (2000)   |
| 2035                     | Riordan, John. <i>An Introduction to Combinatorial Analysis</i> (1958), Ch. 1: 1-18  |
| 2036                     | Zyrtec-D FDA Label, Approved August 10, 2001   |
| 2037                     | Argentum Pharmaceuticals, "About," <a href="http://www.argentumpharmaceuticals.com/about/">http://www.argentumpharmaceuticals.com/about/</a> (accessed May 17, 2017)               |
| 2038                     | Khan, M., and Reddy, I. <i>Pharmaceutical and Clinical Calculations</i> (2nd ed., 2000), pp. 149-167 (PTX0194)   |
| 2039                     | Flonase <sup>®</sup> Label 1998, Application Number 20-121/S009, November 1998 (PTX0059)   |
| 2040                     | British Pharmaceutical Codex (1973), "Hypromellose," pp. 232, 307-308 (PTX0193)  |
| 2041                     | Howarth, P. H. "A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis," <i>Allergy</i> , 62: 6-11; 2000 (PTX0337) |
| 2042                     | Nielsen, Lars P. "Review Article, Intranasal Corticosteroids for Allergic Rhinitis - Superior Relief?" <i>Am. J. Respir Med.</i> , 2(1): 55-65; 2001 (PTX0338)                     |

| <b>Cipla's Exhibit #</b> | <b>Description</b>   |
|--------------------------|--|
| 2043                     | Shenfield, G. M. "Fixed drug combinations: which ones can be recommended?" <i>Current Therapeutics</i> , 27(11): 15-29; 1986 (DTX-048)   |
| 2044                     | Michael, Y., <i>et al.</i> "Characterisation of the aggregation behavior in a salmeterol and fluticasone propionate inhalation aerosol system," <i>International Journal of Pharmaceutics</i> , 221: 165-174; 2001 (PTX0179) |
| 2045                     | Hampel, F., <i>et al.</i> "Double-blind, Placebo-Controlled Study of Azelastine and Fluticasone in a Single Nasal Spray Delivery Device," <i>Annals of Allergy, Asthma, &amp; Immunology</i> , 105: 168-173; 2010 (PTX0230)  |
| 2046                     | Weiler, J. M., <i>et al.</i> "Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis," <i>Ann. Allergy Asthma Immunol</i> , 79: 327-332; 1997 (PTX0329)          |
| 2047                     | Blaiss, M. "Efficacy, Safety, and Patient Preference of Inhaled Corticosteroids: A Review of Pertinent Published Data," <i>Allergy and Asthma Proc.</i> , 22(6): S5-S10; 2001 (PTX0058)                                      |
| 2048                     | DataMonitor – "Pipeline and Commercial Insight: Allergic Rhinitis," July 2010 (PTX0396)  |
| 2049                     | 2006 Cipla-Meda License Agreement with Quality Agreement (PTX1016)   |
| 2050                     | 2011 First Amendment to Cipla-Meda Agreement (PTX0282)   |
| 2051                     | <i>Physicians' Desk Reference</i> , 54 <sup>th</sup> ed., pp. 2783- 2786 (2000)  |
| 2052                     | Leung, D., <i>et al.</i> "The Editors' Choice: MP29-02: A Major Achievement in the treatment of allergic rhinitis," <i>J. Allergy Clin. Immunol.</i> , 129(5): 1216; 2012 (PTX0029)  |
| 2053                     | Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024, GlobalData, September 2015 (PTX0397)   |
| 2054                     | MedPointe Making Medicine Better: Astelin <sup>®</sup> Day Life CyclePlan, November 1, 2002 (PTX1005)  |

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.